ArticleCancer prevention research (Philadelphia, Pa.)2026
Localized Microbial-Immunometabolic Interactions and Early Lung Cancer.
Article in Cancer prevention research (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The composition of lower airway microbiome has been linked to the development and progression of non-small cell lung cancer (NSCLC). Recent research has transitioned from viewing the lung microbiome as a bystander to a central player in carcinogenesis. Enrichment of oral commensals, specifically Veillonella, Prevotella, and Streptococcus, in the lower airways is associated with upregulated oncogenic pathways and increased inflammatory immune tone. A new integrative multiomic analysis by Weinberg and colleagues involving patients with early-stage NSCLC further supports these associations. By comparing bronchoalveolar lavage fluid from tumor-affected lobes against unaffected lobes within the same patient, researchers identified a localized microbial-immunometabolic niche. Key findings include an enrichment of the Veillonella-Streptococcus-Prevotella taxa and the metabolic byproduct stearic acid (SA) in tumor-affected sites. Ex vivo, SA stimulates macrophages into a "polyfunctional" state, secreting pro-inflammatory cytokines like MIP-1β and RANTES. This secretome could induce neoplastic transformation in lung epithelial cells, facilitating anchorage-independent growth. These insights shift paradigms toward metabolically driven innate immune reprogramming induced by the lung microbiome as an early event in tumor development, offering new strategies for diagnosis, therapy monitoring, and preventive interventions. See related article by Weinberg et al., p. 229 .
Indexed as
Identifiers
42063308What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.